ABEOAbeona Therapeutics Inc
ABEO
Abeona Therapeutics Inc11,003
Mkt Cap
$324.04MVolume
210,606.0052W High
$7.5452W Low
$4.00PE Ratio
5.70ABEO Fundamentals
Price
$5.68Prev Close
$5.86Open
$5.8350D MA
$5.08Beta
0.71Avg. Volume
976,586.51EPS (Annual)
$1.01P/B
1.96Rev/Employee
$25,752.21$182.10
Compact View
Not available
Not available
Earnings Recap
• Reported GAAP EPS of -$0.30 down -25.00% YoY • Reported revenue of $8.72M • Abeona Therapeutics Inc. expects current capital resources to fund operations for at least 12 months. The company plans to file an IND for ABO-701 and commence first-in-human studies in the second half of 2027.
Bullish
Abeona Therapeutics Inc. achieved its first product revenue from ZEVASKYN, expanded qualified treatment centers, and advanced its ABO-701 T-cell therapy for prostate cancer into preclinical development.
Bearish
Abeona Therapeutics Inc. experienced increased net and operating losses, driven by a significant rise in selling, general, and administrative expenses, alongside continued negative operating cash flows.